Concentrations of 2-hydroxyglutarate enantiomers, currently a recognized gliomas biomarker, are elevated by orders of magnitude in gliomas harboring mutations in isocitrate dehydrogenase1/2 (IDH1/2) [34]. This evidence concerns the gene IDH1 and central nervous system cancer.